There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on La Jolla Pharma (LJPC) and Odonate Therapeutics Llc (ODT) with bullish sentiments.
La Jolla Pharma (LJPC)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on La Jolla Pharma yesterday and set a price target of $30. The company’s shares opened today at $6.09, close to its 52-week low of $5.01.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.9% and a 52.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on La Jolla Pharma is a Moderate Buy with an average price target of $18.20, implying a 198.9% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
Odonate Therapeutics Llc (ODT)
In a report released yesterday, Marc Frahm from Cowen & Co. reiterated a Buy rating on Odonate Therapeutics Llc. The company’s shares opened today at $17.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of 11.9% and a 69.0% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Unum Therapeutics Inc, and Blueprint Medicines.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Odonate Therapeutics Llc with a $31 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
